|Mr. Kevin Ali||CEO & Director||N/A||N/A||1960|
|Mr. Matthew M. Walsh||Chief Financial Officer||N/A||N/A||1967|
|Ms. Rachel A. Stahler||Chief Information Officer||N/A||N/A||1976|
|Ms. Jennifer Halchak||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Deborah H. Telman||Gen. Counsel & Company Sec.||N/A||N/A||1966|
|Mr. Aaron Falcione||Chief HR Officer||N/A||N/A||1971|
|Ms. Susanne Gabriele Fiedler||Chief Commercial Officer||N/A||N/A||1968|
|Dr. Sandra Milligan J.D., M.D.||Head of R&D||N/A||N/A||1964|
|Mr. Joseph T. Morrissey Jr.||Head of Manufacturing & Supply||N/A||N/A||1965|
|Mr. Vittorio Nisita||Head of Global Bus. Services||N/A||N/A||1968|
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Organon & Co.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.